Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 14, 2025; 31(2): 100827
Published online Jan 14, 2025. doi: 10.3748/wjg.v31.i2.100827
Exploring gut microbiota as a novel therapeutic target in Crohn’s disease: Insights and emerging strategies
Tong Qiao, Xian-Hui Wen
Tong Qiao, Department of Clinical Medicine, Jinan University, Guangzhou 510632, Guangdong Province, China
Xian-Hui Wen, College of Life Science and Technology, Jinan University, Guangzhou 510632, Guangdong Province, China
Author contributions: Qiao T wrote the first draft of the manuscript; Wen XH reviewed and revised the final manuscript. All authors listed on the manuscript have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xian-Hui Wen, PhD, College of Life Science and Technology, Jinan University, No. 601 Huangpu Avenue West, Tianhe District, Guangzhou 510632, Guangdong Province, China. 17818521036@163.com
Received: August 28, 2024
Revised: September 30, 2024
Accepted: November 15, 2024
Published online: January 14, 2025
Processing time: 112 Days and 22 Hours
Core Tip

Core Tip: Crohn’s disease (CD) represents a complex and challenging medical condition, characterized by the intricate interplay between genetic predisposition, gut microbiota dysbiosis, and immune dysregulation. This paper discusses the key effects of the gut microbiota on CD, as well as how they affect creeping fat. Furthermore, the paper highlights the urgent need to address gut microbiota imbalances, particularly focusing on pathogenic species and their mechanisms, as a critical therapeutic target. The findings underscore the importance of a personalized approach to CD management, emphasizing the need for continued research and innovation to address this complex disease.